- Once-weekly REZZAYO® demonstrated non-inferiority in global response* at day 14 compared to once-daily caspofungin (with optional step-down to oral fluconazole after 3 days or more); primary efficacy outcome met2
- REZZAYO® was generally well tolerated in the clinical trial programes2,3
*Data Review Committee-assessed global response consisted of clinical response as assessed by the investigator, radiological response (for patients with invasive candidiasis documented by radiological or imaging evidence at baseline), and mycological eradication. Rates at day 14 in the modified intent-to-treat (mITT) population: REZZAYO®, 55/93 adult patients (59.1%); caspofungin, 57/94 adult patients (60.6%). Weighted treatment difference -1.1%; 95% CI -14.9 to 12.7.2
Interested in learning more about how REZZAYO® could help in your hospital?
Request an appointment with a Napp representative
Learn more about the impact of REZZAYO® in invasive candidiasis
REZZAYO® may have the potential to change the antifungal care pathway in your hospital.
Efficacy, safety and tolerability
The benefits of a once-weekly therapeutic, without compromising efficacy.1,2
Spectrum of activity
Demonstrated activity across a broad range of Candida species, including some harder-to-treat species, such as C. glabrata and C. parapsilosis.3–5
Dosing
The need for dose adjustments of REZZAYO® is considered unlikely when co-administered with other medicinal products and not required for special populations.1†
Studies and trials
Learn more about the pivotal phase III ReSTORE trial, published in The Lancet, and the pre-planned pooled analysis of STRIVE (phase II) and the ReSTORE trial.
Resources
Watch or listen to expert presentations and opinions on REZZAYO®, and access dedicated learning resources or materials for your patients.
*No dose adjustments for patients with hepatic or renal impairment, elderly (≥65 years) or obese (body mass index ≥30) patients, and can be administered independently of the timing of haemodialysis.1
†REZZAYO® The need for dose adjustments is considered unlikely for medicinal products that are substrates for the CYP2C8, CYP3A4, CYP1A2, and CYP2B6 enzymes and P-gp, BCRP, OATP, OCT1, OCT2, MATE1, and MATE2 transporter proteins, when administered with rezafungin. The drug-drug interaction potential of rezafungin with a number of co-administered medicinal products has also been assessed clinically. The need for dose adjustments is considered unlikely for tacrolimus, cyclosporine, ibrutinib, mycophenolate mofetil, and venetoclax when administered with rezafungin.1
BCRP, breast cancer resistance protein; CYP, cytochrome P450; DDI, drug–drug interaction; IV, intravenous; MATE; multi-drug and toxin extrusion protein; mITT, modified intent-to-treat; OATP, organic anion transporting polypeptides; OCT, Organic Cation Transporter; P-gp, P-glycoprotein.
- REZZAYO® (rezafungin). Summary of Product Characteristics. Napp 2024.
- Thompson GR III, et al. Lancet. 2023;401(10370):49–59.
- Thompson GR III, et al. Lancet Infect Dis. 2023; doi: 10.1016/S1473-3099(23)00551-0.
- Fioriti S, et al. J Fungi (Basel). 2022;8(10):1077.
- Govrins M and Lass-Flörl C. Nat Rev Microbiol. 2023 Sep 6. doi: 10.1038/s41579-023-00961-8.
- Flanagan S, et al. Microbiol Spectr. 2023;11(3): e0133923.
Adverse events should be reported. Reporting forms and information can be found at http://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.
®: REZZAYO is a Registered Trademark of Cidara Therapeutics, Inc., used under license